AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Organogenesis Holdings Inc.
Video analysis: ORGO
All videosNo video analysis for this stock yet. Request one from our team.
News: ORGO
BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO
BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 7,249,528 shares of the company's stock, valued at approximately $17,616,000. BlackRock Inc. owned 5.63% of Organogenesis as of its most recent
Organogenesis Q2 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal of Wound Care demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two wound duration strata studied, providing compelling new peer-reviewed evidence for one of the most difficult-to-treat wound populations in chronic wound care.
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th.
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepted for review the Company's Biologics License Application (BLA) for ReNu®, a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis (OA).
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges.
